SER-603
/ Seres Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 12, 2026
Accordingly, the Company's strategy moving forward will prioritize advancing its early-stage programs, including SER-603 that targets inflammatory and immune indications such as ulcerative colitis, Crohn's disease, and immune checkpoint related enterocolitis (irEC). Discussions are ongoing with counterparties related to potential collaborations in these areas.
(GlobeNewswire)
Pipeline update • Crohn's disease • Ulcerative Colitis
1 to 1
Of
1
Go to page
1